Indeed, Lee and Ahn showed that AAV2 modified with a streptavidin–biotin complex linked to an anti-EpCAM antibody was substantially effective at targeting EpCAM-positive ovarian cancer cells15. This evidence concerns the gene EPCAM and ovarian carcinoma.